Time to Initial Clinician-Reported Inactivation of Neovascular Age-Related Macular Degeneration Treated Primarily with Ranibizumab
Mark C Gillies, Anna Campain, Richard Walton, Judy M Simpson, Jennifer J Arnold, Robyn H Guymer, Ian L McAllister, Alex P Hunyor, Rohan W Essex, Nigel Morlet, Daniel Barthelmes
Ophthalmology | ELSEVIER SCIENCE INC | Published : 2015
Awarded by National Health and Medical Research Council
M.C.G.: Sydney Medical Foundation Fellow; Support - NHMRC practitioner fellowship; Advisory board - Novartis, Bayer, and Allergan.J.J.A.: Personal fees and nonfinancial support - Novartis Pharmaceuticals and Bayer Pharmaceuticals, outside the submitted work.A.P.H.: Support - Novartis and Bayer.D.B.: Support - Walter and Gertrud Siegenthaler Foundation, Zurich, Switzerland, and the Swiss National Foundation.Supported by a grant from the Royal Australian and New Zealand College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council (grant no. 632663), Australia (NHRMC 2010-2012). Funding was also provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research.